Withdrawal of non-binding proposal

26^th Aug 2015

In the Company’s announcement of the conclusion of its strategic review released on 18 August, 2015, reference was made to a non-binding preliminary proposal of US$110 million for the Company’s Point-of-Care business. That proposal has now been withdrawn.

The proposals referenced in the Company’s announcements released on 24 August, 2015 are not affected.

Back to Listing

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

Liverpool FC players put to the (lactate) test

LOGISTICS: A total meltdown

EKF globally launches STAT-Site® WB β-ketone and glucose handheld analyzer

EKF obtains CE mark certification alongside CLIA waiver for easy-to-use whole blood analyzer for diabetes care programmes

EKF opens larger facility to increase production of key component for COVID-19 testing regime

EKF’s new facilities in Llandough, Cardiff, for manufacture of PrimeStore^® MTM viral transport media, enabling pathogenic samples to be collected and transported safely and easily in compliance with UN3373 packaging regulations.

EKF fly the extra mile over Christmas

New COVID-SeroKlir SARS-CoV-2 IgG antibody test kit is one of first to detect both the presence and precise levels of COVID-19 neutralizing antibodies